Systemic bias in randomized clinical trials in different fields of medicine in 2014—2024: a narrative review

Lantsova E.V.; Smirnova N.G.; Lebedinskii K.M.

doi:https://doi.org/10.17116/anaesthesiology202406179

Рекомендуем статьи по данной теме:

Использование двойного ингибирования VEGF-A и ангиопоэтина-2 в лечении неоваскулярной возрастной макулярной дегенерации и диабетического макулярного отека. Вестник офтальмологии. 2024;(6):100-106

Фармакоэпидемиологическое исследование безопасности оксалиплатина (анализ российской базы спонтанных сообщений). Медицинские технологии. Оценка и выбор. 2025;(1):76-83

Эффективность комбинированной химиоиммунотерапии и поиск персонифицированного подхода к лечению распространенного немелкоклеточного рака легкого. Онкология. Журнал им. П.А. Герцена. 2025;(4):37-45

Резюме / Abstract:

ЦЕЛЬ ИССЛЕДОВАНИЯ

Выполнить анализ источников рисков систематической ошибки в современных рандомизированных исследованиях, наличие которой может привести к искажению результатов по отношению к реальной клинической практике.

МАТЕРИАЛ И МЕТОДЫ

Для оценки риска применяли инструмент Rob2, представленный в рекомендациях Cochrane Handbook for Systematic Reviews of Interventions. Из найденных 2555 исследований в обзор включено 25. Для примеров каждого вида систематической ошибки выбрано по одной статье, относящейся к каждой из пяти выбранных тем: онкология, кардиология, эндокринология, COVID-19, применение биологических препаратов при различных заболеваниях (терапия, инфекционные болезни).

РЕЗУЛЬТАТЫ

Выявлена основная критическая зона клинических исследований, в которой наличие систематической ошибки приводит к несопоставимости популяций субъектов клинических исследований и пациентов реальной практики.

ЗАКЛЮЧЕНИЕ

Показано, что только объединение результатов клинических исследований и реальной практики позволит провести достоверную оценку полученных данных.

Ключевые слова / Keywords:

доказательная медицина

рандомизированные клинические исследования

систематическая ошибка

реальная клиническая практика

Авторы / Authors:

Ланцова Е.В.

ООО «Сайнсфайлз»

ORCID: 0000-0002-1412-0711

Смирнова Н.Г.

ООО «Сайнсфайлз»

ORCID: 0009-0008-0075-9638

Лебединский К.М.

ФГБОУ ВО «Северо-Западный государственный медицинский университет им. И.И. Мечникова» Минздрава России

SPIN РИНЦ: 3590-2308
Scopus AuthorID: 6602775085
ResearcherID: O-8655-2014
ORCID: 0000-0002-5752-4812

Дата поступления:

07.06.2024

Дата принятия в печать:

17.07.2024

Закрыть метаданные

Литература / References:

АОКИ. Итоги 2023 года. Информационно-аналитический бюллетень №28. М. 2024. Ссылка активна на 27.09.24. https://acto-russia.org/files/bulletin_28.pdf
Хараз А.Д., Гришунина А.А. Клинические исследования: прошлое и будущее. Глобальные тренды. Московская медицина. 2023;58(6). Ссылка активна на 27.09.24. https://niioz.ru/moskovskaya-meditsina/zhurnal-moskovskaya-meditsina/obzor/klinicheskie-issledovaniya-proshloe-i-budushchee-globalnye-trendy/?ysclid=lvufxhyq35645892735
Яковлев С.В., Суворова М.П. Ренессанс спирамицина в клинической практике. Антибиотики и химиотерапия. 2023;68(7-8):83-89. https://doi.org/10.37489/0235-2990-2023-68-7-8-83-89
Архипов В.В., Айсанов З.Р., Авдеев С.Н. Эффективность комбинаций ингаляционных глюкокортикостероидов и длительно действующих β-агонистов в условиях реальной медицинской практики: результаты многоцентрового кросс-секционного исследования у российских пациентов с бронхиальной астмой. Пульмонология. 2021;31(5):613-626. https://doi.org/10.18093/0869-0189-2021-31-5-613-626
Павлова Т.В. Роль исследований реальной клинической практики в доказательной кардиологии. Российский кардиологический журнал. 2021;S3:86-92. https://doi.org/10.15829/1560-4071-2021-4636
Ward T, Medina-Lara A, Mujica-Mota RE, Spencer AE. Accounting for Heterogeneity in Resource Allocation Decisions: Methods and Practice in UK Cancer Technology Appraisals. Value Health. 2021;24(7):995-1008. https://doi.org/10.1016/j.jval.2020.12.022
Гиляревский С.Р. Назначение лекарственных препаратов по показаниям, не указанным в инструкции («off-label»): сложная проблема современной клинической практики. Рациональная фармакотерапия в кардиологии. 2020;16(2):324-334. https://doi.org/10.20996/1819-6446-2020-04-14
Беллетти А., Аццолини М.Л., Балдетти Л., Ландони Д., Франко А., Дзангрилло А. Применение инотропных препаратов и вазопрессоров в реаниматологии и периоперационной медицине: доказательный подход (обзор). Общая реаниматология. 2022;18(5):60-77. https://doi.org/10.15360/1813-9779-2022-5-60-77
Mitchell AP, Harrison MR, George DJ, Abernethy AP, Walker MS, Hirsch BR. Clinical Trial Subjects Compared to “Real World” Patients: Generalizability of Renal Cell Carcinoma Trials. Journal of Clinical Oncology. 2014; 32:6510-6510. https://doi.org/10.1200/jco.2014.32.15_suppl.6510
Cochrane Handbook for Systematic Reviews of Interventions. Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, eds. 2nd Edition. Chichester (UK): John Wiley & Sons; 2021. Accessed September 27, 2024. https://training.cochrane.org/handbook/current
Esperion Therapeutics, Inc. A Randomized, Double-blind, Placebo-controlled Study to Assess the Effects of Bempedoic Acid (ETC-1002) on the Occurrence of Major Cardiovascular Events in Patients With, or at High Risk for, Cardiovascular Disease Who Are Statin Intolerant: Clinical trial registration NCT02993406. 2023. Accessed September 27, 2024. https://clinicaltrials.gov
AstraZeneca. A Phase III Randomized, Double-blind, Placebo-controlled, Multi-center Study in Adults to Determine the Safety and Efficacy of AZD7442, a Combination Product of Two Monoclonal Antibodies (AZD8895 and AZD1061), for Post-exposure Prophylaxis of COVID-19: Clinical trial registration NCT04625972. 2023. Accessed September 27, 2024. https://clinicaltrials.gov
Hutchison Medipharma Limited. A Global Multicenter Randomized Placebo-Controlled Phase 3 Trial To Compare The Efficacy And Safety Of Fruquintinib Plus Best Supportive Care To Placebo Plus Best Supportive Care In Patients With Refractory Metastatic Colorectal Cancer: Clinical trial registration NCT04322539. 2023. Accessed September 27, 2024. https://clinicaltrials.gov
GlaxoSmithKline. A Long Term, Randomised, Double Blind, Placebo-controlled Study to Determine the Effect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Patients with Type 2 Diabetes Mellitus: Clinical trial registration NCT02465515. 2019. Accessed September 27, 2024. https://clinicaltrials.gov,2019
Sanofi Pasteur, a Sanofi Company. Immune Lot Consistency, Immunogenicity, and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Adolescents and Adults Aged 10 to 55 Years: Clinical trial registration NCT02842853. 2022. Accessed September 27, 2024. https://clinicaltrials.gov
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company. A Prospective, Randomized, Open-Label, Blinded Endpoint Evaluation (PROBE) Parallel Group Study Comparing Edoxaban vs. VKA in Subjects Undergoing Catheter Ablation of Non-valvular Atrial Fibrillation (ELIMINATE-AF): Clinical trial registration NCT02942576. 2019. Accessed September 27, 2024. https://clinicaltrials.gov
InflaRx GmbH. A Pragmatic Adaptive Randomized, Controlled Phase II/III Multicenter Study of IFX-1 in Patients With Severe COVID-19 Pneumonia: Clinical trial registration NCT04333420. 2023. Accessed September 27, 2024. https://clinicaltrials.gov
Merck Sharp & Dohme LLC. A Randomized, Double-Blind, Phase III Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer — (KEYNOTE-355): Clinical trial registration NCT02819518. 2023. Accessed September 27, 2024. https://clinicaltrials.gov
Novo Nordisk A/S. A 38 Week Trial Comparing Effect and Safety of Insulin Degludec/Insulin Aspart vs. Insulin Glargine Plus Insulin Aspart in Subjects With Type 2 Diabetes Treated With Basal Insulin With or Without Oral Antidiabetic Treatment in Need of Treatment Intensification: Clinical trial registration NCT02906917. 2019. Accessed September 27, 2024. https://clinicaltrials.gov
AbbVie. A Phase 3, Randomized, Active-Controlled, Double-Blind Study Comparing Upadacitinib (ABT-494) to Abatacept in Subjects With Moderately to Severely Active Rheumatoid Arthritis With Inadequate Response or Intolerance to Biologic DMARDs (bDMARDs) on Stable Conventional Synthetic Disease Modifying Anti-Rheumatic Drugs (csDMARDs): Clinical trial registration NCT03086343. 2023. Accessed September 27, 2024. https://clinicaltrials.gov
Resverlogix Corp. A Phase III Multi-Center, Double-Blind, Randomized, Parallel Group, Placebo-Controlled Clinical Trial in High-Risk Type 2 Diabetes Mellitus (T2DM) Subjects With Coronary Artery Disease (CAD) to Determine Whether Bromodomain Extraterminal Domain (BET) Inhibition Treatment With RVX000222 Increases the Time to Major Adverse Cardiovascular Events (MACE): Clinical trial registration NCT02586155. 2021. Accessed September 27, 2024. https://clinicaltrials.gov
Vir Biotechnology, Inc. A Phase II/III Randomized, Multi-center, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of Monoclonal Antibody VIR-7831 for the Early Treatment of Coronavirus Disease 2019 (COVID-19) in Non-hospitalized Patients: Clinical trial registration NCT04545060. 2022. Accessed September 27, 2024. https://clinicaltrials.gov
Ferring Pharmaceuticals. A Multi-Center, Randomized, Assessor-Blind, Controlled Trial Comparing the Occurrence of Major Adverse Cardiovascular Events (MACEs) in Patients with Prostate Cancer and Cardiovascular Disease Receiving Degarelix (Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist) or Leuprolide (GnRH Receptor Agonist): Clinical trial registration NCT02663908. 2022. Accessed September 27, 2024. https://clinicaltrials.gov
Lexicon Pharmaceuticals. A Randomized, Double-blind, Placebo-controlled, 3-arm, Parallel-group 52-week Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin in Patients With Type 2 Diabetes Mellitus and Moderate Renal Impairment Who Have Inadequate Glycemic Control: Clinical trial registration NCT03242252. 2021. Accessed September 27, 2024. clinicaltrials.gov
AbbVie. A Phase 3, Randomized, Double-Blind Study Comparing Risankizumab to Placebo in Subjects With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) (KEEPsAKE 2): Clinical trial registration NCT03671148. 2023. Accessed September 27, 2024. https://clinicaltrials.gov
Cytokinetics. A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Omecamtiv Mecarbil on Mortality and Morbidity in Subjects With Chronic Heart Failure With Reduced Ejection Fraction (GALACTIC-HF): Clinical trial registration NCT02929329. 2021. Accessed September 27, 2024. https://clinicaltrials.gov
AstraZeneca. A Phase III Randomized, Double-blind, Placebo-controlled, Multicenter Study to Determine the Safety and Efficacy of AZD7442 for the Treatment of COVID-19 in Non-hospitalized Adults: Clinical trial registration NCT04723394. 2023. Accessed September 27, 2024. https://clinicaltrials.gov
mAbxience Research S.L. A Randomized, Multicenter, Multinational, Double-Blind Study to Assess the Efficacy and Safety of MB02 (Bevacizumab Biosimilar Drug) Versus Avastin® in Combination With Carboplatin and Paclitaxel for the Treatment of Subjects With Stage IIIB/IV Non-squamous Non-Small Cell Lung Cancer (NSCLC): Clinical trial registration NCT03296163. 2021. Accessed September 27, 2024. https://clinicaltrials.gov
Janssen Research & Development, LLC. A Randomized, Multicenter, Double-Blind, Parallel, Placebo-Controlled Study of the Effects of Canagliflozin on Renal Endpoints in Adult Subjects With Type 2 Diabetes Mellitus: Clinical trial registration NCT01989754. 2018. Accessed September 27, 2024. https://clinicaltrials.gov
Gilead Sciences. Combined Phase 2b/3, Double-Blind, Randomized, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Subjects With Moderately to Severely Active Ulcerative Colitis: Clinical trial registration NCT02914522. 2021. Accessed September 27, 2024. https://clinicaltrials.gov
AstraZeneca. Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients With Chronic Heart Failure With Reduced Ejection Fraction: Clinical trial registration NCT03036124. 2020. Accessed September 27, 2024. https://clinicaltrials.gov
Saint Luke’s Health System. An International, Multicenter, Randomized, Double-blind, Placebo-controlled, Phase III Study Evaluating the Efficacy and Safety of Dapagliflozin in Respiratory Failure in Patients With COVID-19: Clinical trial registration NCT04350593. 2022. Accessed September 27, 2024. https://clinicaltrials.gov
SOTIO a.s. A Randomized, Double Blind, Multicenter, Parallel-group, Phase III Study to Evaluate Efficacy and Safety of DCVAC/PCa Versus Placebo in Men With Metastatic Castration Resistant Prostate Cancer Eligible for 1st Line Chemotherapy: Clinical trial registration NCT02111577. 2021. Accessed September 27, 2024. https://clinicaltrials.gov
Novo Nordisk A/S. A Trial Investigating the Cardiovascular Safety of Oral Semaglutide in Subjects with Type 2 Diabetes: Clinical trial registration NCT02692716. 2022. Accessed September 27, 2024. https://clinicaltrials.gov
Astellas Pharma Inc. Phase 3 Study of ASP015K — A Randomized, Double-blind, Placebo-controlled Confirmatory Study of the Efficacy and Safety of ASP015K in Patients with Rheumatoid Arthritis Who Had an Inadequate Response to MTX: Clinical trial registration NCT02305849. 2020. Accessed September 27, 2024. https://clinicaltrials.gov
Nissen SE, Menon V, Nicholls SJ, Brennan D, Laffin L, Ridker P, Ray KK, Mason D, Kastelein JJP, Cho L, Libby P, Li N, Foody J, Louie MJ, Lincoff AM. Bempedoic Acid for Primary Prevention of Cardiovascular Events in Statin-Intolerant Patients. JAMA. 2023; 11;330(2):131-140. https://doi.org/10.1001/jama.2023.9696
Nissen SE, Lincoff AM, Brennan D, Ray KK, Mason D, Kastelein JJP, Thompson PD, Libby P, Cho L, Plutzky J, Bays HE, Moriarty PM, Menon V, Grobbee DE, Louie MJ, Chen CF, Li N, Bloedon L, Robinson P, Horner M, Sasiela WJ, McCluskey J, Davey D, Fajardo-Campos P, Petrovic P, Fedacko J, Zmuda W, Lukyanov Y, Nicholls SJ; CLEAR Outcomes Investigators. Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients. New England Journal of Medicine. 2023;388(15):1353-1364. https://doi.org/10.1056/NEJMoa2215024
Levin MJ, Ustianowski A, Thomas S, Templeton A, Yuan Y, Seegobin S, Houlihan CF, Menendez-Perez I, Pollett S, Arends RH, Beavon R, Dey K, Garbes P, Kelly EJ, Koh GCKW, Ivanov S, Near KA, Sharbaugh A, Streicher K, Pangalos MN, Esser MT; COVID-19 Study to Optimally Reduce Morbidity in CareHomes and Sites with Enhanced Risk (STORMCHASER) Study Group. AZD7442 (Tixagevimab/Cilgavimab) for Post-Exposure Prophylaxis of Symptomatic Coronavirus Disease 2019. Clinical Infectious Diseases. 2023;76(7):1247-1256. https://doi.org/10.1093/cid/ciac899
Dasari A, Sobrero A, Yao J, Yoshino T, Schelman W, Yang Z, Chien C, Kania M, Tabernero J, Eng C. FRESCO-2: a global Phase III study investigating the efficacy and safety of fruquintinib in metastatic colorectal cancer. Future Oncology. 2021;17(24):3151-3162. https://doi.org/10.2217/fon-2021-0202
Hernandez AF, Green JB, Janmohamed S, D’Agostino RB Sr, Granger CB, Jones NP, Leiter LA, Rosenberg AE, Sigmon KN, Somerville MC, Thorpe KM, McMurray JJV, Del Prato S; Harmony Outcomes committees and investigators. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet. 2018;392(10157):1519-1529. https://doi.org/10.1016/S0140-6736(18)32261-X
Dhingra MS, Peterson J, Hedrick J, Pan J, Neveu D, Jordanov E. Immunogenicity, safety and inter-lot consistency of a meningococcal conjugate vaccine (MenACYW-TT) in adolescents and adults: A Phase III randomized study. Vaccine. 2020;38(33):5194-5201. https://doi.org/10.1016/j.vaccine.2020.06.013
Thompson D. Replication of Randomized, Controlled Trials Using Real-World Data: What Could Go Wrong? Value in Health. 2021;24(1):112-115. https://doi.org/10.1016/j.jval.2020.09.015
Stone AA, Schneider S, Smyth JM, Junghaenel DU, Wen C, Couper MP, Goldstein S. Shedding light on participant selection bias in Ecological Momentary Assessment (EMA) studies: Findings from an internet panel study. PLoS One. 2023;18(3): e0282591. https://doi.org/10.1371/journal.pone.0282591
Margolis D-RJ. Understanding the Need for Non-Interventional Studies Using Secondary Data to Generate Real-World Evidence for Regulatory Decision Making, and Demonstrating Their Credibility. Accessed September 27, 2024. https://healthpolicy.duke.edu/publications/understanding-need-non-interventional-studies-using-secondary-data-generate-real-world
Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, Chapman MJ, De Backer GG, Delgado V, Ference BA, Graham IM, Halliday A, Landmesser U, Mihaylova B, Pedersen TR, Riccardi G, Richter DJ, Sabatine MS, Taskinen MR, Tokgozoglu L, Wiklund O; ESC Scientific Document Group. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. European Heart Journal of Cardiovascular Imaging. 2020;41(1):111-188. https://doi.org/10.1093/eurheartj/ehz455
Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, Braun LT, de Ferranti S, Faiella-Tommasino J, Forman DE, Goldberg R, Heidenreich PA, Hlatky MA, Jones DW, Lloyd-Jones D, Lopez-Pajares N, Ndumele CE, Orringer CE, Peralta CA, Saseen JJ, Smith SC Jr, Sperling L, Virani SS, Yeboah J. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139(25):e1082-e1143. https://doi.org/10.1161/CIR.0000000000000625
Цыганкова О.В., Апарцева Н.Е., Аметов А.С. Гипертриглицеридемия — новое и важное настоящее. Эндокринология: новости, мнения, обучение. 2023;12(4):99-111. https://doi.org/10.33029/2304-9529-2023-12-4-99-111
Watanabe JH, Simon GE, Horberg M, Platt R, Hernandez A, Califf RM. When Are Treatment Blinding and Treatment Standardization Necessary in Real-World Clinical Trials? Clinical Pharmacology and Therapeutics. 2022;111(1):116-121. https://doi.org/10.1002/cpt.2256
Banack HR, Kaufman JS, Wactawski-Wende J, Troen BR, Stovitz SD. Investigating and Remediating Selection Bias in Geriatrics Research: The Selection Bias Toolkit. Journal of the American Geriatrics Society. 2019;67(9):1970-1976. https://doi.org/10.1111/jgs.16022
Tashkin DP, Amin AN, Kerwin EM. Comparing Randomized Controlled Trials and Real-World Studies in Chronic Obstructive Pulmonary Disease Pharmacotherapy. International Journal of Chronic Obstructive Pulmonary Disease. 2020;15:1225-1243. https://doi.org/10.2147/COPD.S244942
Vonbank A, Drexel H, Agewall S, Lewis BS, Dopheide JF, Kjeldsen K, Ceconi C, Savarese G, Rosano G, Wassmann S, Niessner A, Schmidt TA, Saely CH, Baumgartner I, Tamargo J. Reasons for disparity in statin adherence rates between clinical trials and real-world observations: a review. European Heart Journal — Cardiovascular Pharmacotherapy. 2018;4(4):230-236. https://doi.org/10.1093/ehjcvp/pvy028
El Dib R, Jorge EC, Kamegasawa A, Daher SR, Spagnuolo RS, Silva MP, Braga GP, Volpato E, Módolo NS, Betini M, Valle Ad, Corrêa I, Bazan R, Almeida RA, Weber SA, Molina S, Yoo H, Villas Boas P, Corrente JE, Mathew J, Kapoor A, Carvalho R, Vital RB, Braz LG, Junior Pdo N. Differences between the real and the desired worlds in the results of clinical trials. Clinics (Sao Paulo). 2015;70(9):618-622. https://doi.org/10.6061/clinics/2015(09)04
Selker HP, Eichler HG, Stockbridge NL, McElwee NE, Dere WH, Cohen T, Erban JK, Seyfert-Margolis VL, Honig PK, Kaitin KI, Oye KA, D’Agostino RB Sr. Efficacy and Effectiveness Too Trials: Clinical Trial Designs to Generate Evidence on Efficacy and on Effectiveness in Wide Practice. Clinical Pharmacology and Therapeutics. 2019;105(4):857-866. https://doi.org/10.1002/cpt.1347
Collins R, Bowman L, Landray M, Peto R. The Magic of Randomization versus the Myth of Real-World Evidence. New England Journal of Medicine. 2020;382(7):674-678. https://doi.org/10.1056/NEJMsb1901642
Bruix J. Endpoints in clinical trials for liver cancer and their value in evidence-based clinical decision making: An unresolved Gordian knot. Journal of Hepatology. 2021;74(6):1483-1488. https://doi.org/10.1016/j.jhep.2021.01.033
Risk of bias tools — Current version of RoB 2. Accessed September 27, 2024. https://sites.google.com/site/riskofbiastool/welcome/rob-2-0-tool/current-version-of-rob-2
Husain M, Birkenfeld AL, Donsmark M, Dungan K, Eliaschewitz FG, Franco DR, Jeppesen OK, Lingvay I, Mosenzon O, Pedersen SD, Tack CJ, Thomsen M, Vilsbøll T, Warren ML, Bain SC; PIONEER 6 Investigators. Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine. 2019;381(9):841-851. https://doi.org/10.1056/NEJMoa1901118
Verma S, Fainberg U, Husain M, Rasmussen S, Rydén L, Ripa MS, Buse JB. Applying REWIND cardiovascular disease criteria to SUSTAIN 6 and PIONEER 6: An exploratory analysis of cardiovascular outcomes with semaglutide. Diabetes, Obesity and Metabolism. 2021;23(7):1677-1680. https://doi.org/10.1111/dom.14360
Strain WD, Frenkel O, James MA, Leiter LA, Rasmussen S, Rothwell PM, Sejersten Ripa M, Truelsen TC, Husain M. Effects of Semaglutide on Stroke Subtypes in Type 2 Diabetes: Post Hoc Analysis of the Randomized SUSTAIN 6 and PIONEER 6. Stroke. 2022;53(9):2749-2757. https://doi.org/10.1161/STROKEAHA.121.037775
Thethi TK, Pratley R, Meier JJ. Efficacy, safety and cardiovascular outcomes of once-daily oral semaglutide in patients with type 2 diabetes: The PIONEER programme. Diabetes, Obesity and Metabolism. 2020;22(8):1263-1277. https://doi.org/10.1111/dom.14054
Takeuchi T, Tanaka Y, Tanaka S, Kawakami A, Iwasaki M, Katayama K, Rokuda M, Izutsu H, Ushijima S, Kaneko Y, Shiomi T, Yamada E, van der Heijde D. Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III randomised, double-blind, placebo-controlled trial (RAJ4) in Japan. Annals of the Rheumatic Diseases. 2019;78(10):1305-1319.
Tanaka Y, Takeuchi T, Kato D, Kaneko Y, Fukuda M, Izutsu H, Rokuda M, van der Heijde D. Post hoc analysis of clinical characteristics of patients with radiographic progression in a Japanese phase 3 trial of peficitinib and methotrexate treatment (RAJ4). Modern Rheumatology. 2023;33(1):73-80. https://doi.org/10.1093/mr/roac021
Клинические рекомендации. Ревматоидный артрит. 2023. Одобрено Научно-практическим советом Министерства здравоохранения Российской Федерации. Ссылка активна на 27.09.24. https://cr.minzdrav.gov.ru/schema/250_2
Grouin JM, Coste M, Lewis J. Subgroup analyses in randomized clinical trials: statistical and regulatory issues. Journal of Biopharmaceutical Statistics. 2005;15(5):869-882. https://doi.org/10.1081/BIP-200067988
Temple R. Enrichment of clinical study populations. Clinical Pharmacology and Therapeutics. 2010;88(6):774-778. https://doi.org/10.1038/clpt.2010.233